Compare ALK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALK | DNTH |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.5B |
| IPO Year | 2003 | 2018 |
| Metric | ALK | DNTH |
|---|---|---|
| Price | $52.08 | $91.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $62.92 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.0M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,426,000,000.00 | $2,036,000.00 |
| Revenue This Year | $11.19 | N/A |
| Revenue Next Year | $5.11 | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.09 | N/A |
| 52 Week Low | $33.03 | $18.08 |
| 52 Week High | $65.35 | $96.50 |
| Indicator | ALK | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 60.31 |
| Support Level | $36.64 | $79.27 |
| Resistance Level | $52.86 | $92.41 |
| Average True Range (ATR) | 2.36 | 5.38 |
| MACD | 0.50 | 1.03 |
| Stochastic Oscillator | 94.29 | 94.79 |
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.